• Healthcare
  • HealthTech

Ōura Partners with Stelo to Launch AI-Powered Meal and Glucose Tracking

3 minute read

By Tech Icons
10:58 am
Save

Smart Ring Maker Expands Health Tracking with AI-Powered Food Recognition and 15-Minute Glucose Readings

Three Key Facts

  • Ōura integrates with Stelo by Dexcom to provide AI-driven meal and glucose tracking through its smart ring and app ecosystem
  • New features include AI-powered meal photo recognition and continuous glucose monitoring with readings every 15 minutes
  • Stelo glucose biosensor is available for $99, requiring no prescription and lasting 15 days per sensor

Introduction

A breakthrough in personal health monitoring emerges as Ōura partners with Stelo by Dexcom to transform how users track their metabolic health. The collaboration, detailed in VentureBeat, introduces AI-powered meal tracking and glucose monitoring features that integrate seamlessly with Ōura’s existing health metrics.

Key Developments

The partnership introduces two groundbreaking features: AI-powered meal tracking through photo recognition and continuous glucose monitoring via Dexcom’s biosensor technology. Users can now photograph their meals for instant nutritional analysis, while the Stelo sensor provides glucose readings every 15 minutes directly to the Ōura app.

Holly Shelton, Ōura’s Chief Product Officer, emphasizes the company’s commitment to AI integration: “Our product roadmap for this year is built on a robust investment in AI-forward offerings.” This approach aims to provide users with deeper insights into their nutritional choices and metabolic responses.

Market Impact

With over 800 million people globally facing obesity-related challenges, this integration addresses critical health monitoring needs. The Stelo biosensor, priced at $99 and available without prescription, makes professional-grade glucose monitoring accessible to a broader consumer base.

Jake Leach from Dexcom notes that the integration creates “a personalized metabolic health experience,” combining lifestyle data with precise glucose monitoring in ways previously unavailable to consumers.

Strategic Insights

Ōura’s approach focuses on pattern recognition rather than individual measurements. Shyamal Patel, Ōura’s Senior VP of Science, stresses the importance of understanding long-term trends over isolated readings, promoting a balanced approach to dietary choices.

The integration leverages AI through Ōura Advisor to provide personalized insights, helping users understand how their lifestyle choices affect their metabolic health without prescriptive judgment.

Expert Opinions and Data

Healthcare professionals praise the system’s comprehensive approach to metabolic health monitoring. The technology combines Dexcom’s established glucose monitoring expertise with Ōura’s sophisticated activity and sleep tracking capabilities.

Initial data suggests that users benefit from seeing the direct relationship between their dietary choices and glucose responses. The system’s ability to provide immediate feedback through AI-driven analysis helps users make more informed decisions about their health.

Moving Forward

The Meals and Glucose features are now available on iOS and Android devices in the U.S., with international expansion planned. This integration represents a significant step in making professional-grade health monitoring accessible to consumers, strengthening Ōura’s position in the digital health market.

Related News

Amazon Q1 2026 Shows AWS Reaccelerating on AI Demand

Read more

Amazon Prime Day Expands to Four-Day Shopping Event in 2025

Read more

Samsung Doubles Down on Mobile AI With 800M Device Target

Read more

Apple Shifts iPhone 17 Pro Logo, Misaligning MagSafe

Read more

GSK Expands HIV Injection Access to 133 Nations via Licensing

Read more

India's AI Summit Signals a Shift in Global Tech Power

Read more

HealthTech News

View All
Eli Lilly Q1 2026 results reflecting tirzepatide sales surge, Mounjaro and Zepbound growth, and expanding GLP-1 drug market demand

Eli Lilly Posts 56% Revenue Surge as Incretin Empire Expands

Read more
Novartis Q1 2026 earnings show Novartis Kisqali growth, Novartis Pluvicto sales, Novartis Entresto decline and Novartis pharma growth across Novartis drug portfolio, Novartis financial results, Novartis revenue and growth, Novartis oncology drugs, Novartis patent expiry impact, Novartis growth brands, Novartis drug sales growth and Novartis pharma strategy

Novartis Q1 2026 Earnings Show Growth Beyond Patent Cliff

Read more
OpenAI pharmaceutical partnership Novo Nordisk AI drug discovery healthcare AI digital transformation Novo Nordisk OpenAI alliance AI strategy

Novo Nordisk and OpenAI Join Forces to Reshape Drug Discovery

Read more